



## ASH 2017 Day Two Update Atlanta, GA

**Dr. Brian Koffman** – Hi. I'm Dr. Brian Koffman, the founder and medical director of the CLL Society. And I'm here to report at the end of a long second day of ASH, the American Society Hematology annual meeting and exposition in Atlanta, Georgia. And the snow has stopped, but it's still bitter cold. But that doesn't dampen my enthusiasm for what I wanted to share with you that I found out today.

Today was the first day that there was clinical presentations, oral posters and abstracts that talked about what was going on in CLL. And I'll be summarizing these in more details over the coming weeks in interviewing some of the doctors who are the lead investigators on this. But what you need to know from this information is that the direction that research is going in CLL is no longer looking at monotherapy but starting to look at combinations.

There are really exciting data for combinations of chemoimmunotherapy, specifically FCR and combinations with Ibrutinib. Dr. Matt Davids presented data there, where over 80 percent of patients that were appropriate for this therapy got to MRD negative complete remissions. This is unheard of results with only six months' worth of therapy.

And in the non-chemo area, there are astonishing results with the combinations of Ibrutinib and Venetoclax, or using some of the new antibodies like Obinutuzumab.

So, I'll give more of the details of this over the next few weeks, but let's just say the future looks very good in the CLL world.

Thanks. Dr. Brian Koffman.

And I'll talk to you again tomorrow night.